MIRA MIRA Pharmaceuticals Inc.: Net earnings per share for the last 12 months

Demand for neuropathic pain treatments remains stable and independent of macroeconomic conditions. MIRA Pharmaceuticals is currently developing synthetic analogs of ketamine and THC to combat depression without inducing hallucinations. Developing drugs across various niches mitigates overall risk. The EPS YoY TTM growth trajectory visualizes profit dynamics, where the -186.60 metric indicates the status of the current market phase.
MIRA Pharmaceuticals - analytical breakdowns and key metrics (MIRA)

This indicator measures the rolling year net earnings per share dynamics, allowing investors to assess business capitalization efficiency and the rate of change in profitability. Analyzing the annual EPS growth rate over the last 12 months helps identify a trend reversal in demand for MIRA Pharmaceuticals non-opioid analgesics prior to the publication of reports, confirming the successful commercialization of patented cannabinoids.